Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.69 USD
−29.77 M USD
0.00 USD
2.90 M
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MBRX is 2.73 USD — it has decreased by −3.53% in the past 24 hours. Watch Moleculin Biotech, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Moleculin Biotech, Inc. stocks are traded under the ticker MBRX.
MBRX stock has fallen by −14.15% compared to the previous week, the month change is a 7.06% rise, over the last year Moleculin Biotech, Inc. has showed a −65.04% decrease.
We've gathered analysts' opinions on Moleculin Biotech, Inc. future price: according to them, MBRX price has a max estimate of 28.00 USD and a min estimate of 8.00 USD. Watch MBRX chart and read a more detailed Moleculin Biotech, Inc. stock forecast: see what analysts think of Moleculin Biotech, Inc. and suggest that you do with its stocks.
MBRX reached its all-time high on Jun 6, 2016 with the price of 862.20 USD, and its all-time low was 2.12 USD and was reached on Aug 1, 2024. View more price dynamics on MBRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MBRX stock is 8.56% volatile and has beta coefficient of 1.28. Track Moleculin Biotech, Inc. stock price on the chart and check out the list of the most volatile stocks — is Moleculin Biotech, Inc. there?
Today Moleculin Biotech, Inc. has the market capitalization of 8.20 M, it has increased by 4.43% over the last week.
Yes, you can track Moleculin Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
Moleculin Biotech, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
MBRX earnings for the last quarter are −2.85 USD per share, whereas the estimation was −2.44 USD resulting in a −16.80% surprise. The estimated earnings for the next quarter are −1.26 USD per share. See more details about Moleculin Biotech, Inc. earnings.
Moleculin Biotech, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MBRX net income for the last quarter is −10.59 M USD, while the quarter before that showed −4.32 M USD of net income which accounts for −145.24% change. Track more Moleculin Biotech, Inc. financial stats to get the full picture.
No, MBRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 18.00 employees. See our rating of the largest employees — is Moleculin Biotech, Inc. on this list?
Like other stocks, MBRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Moleculin Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Moleculin Biotech, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Moleculin Biotech, Inc. stock shows the sell signal. See more of Moleculin Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.